Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2015

Open Access 01-12-2015 | Study protocol

A core outcome set for localised prostate cancer effectiveness trials: protocol for a systematic review of the literature and stakeholder involvement through interviews and a Delphi survey

Authors: Steven MacLennan, Hendrika J Bekema, Paula R Williamson, Marion K Campbell, Fiona Stewart, Sara J MacLennan, James MO N’Dow, Thomas BL Lam

Published in: Trials | Issue 1/2015

Login to get access

Abstract

Background

Prostate cancer is a growing health problem worldwide. The management of localised prostate cancer is controversial. It is unclear which of several surgical, radiotherapeutic, ablative, and surveillance treatments is the most effective. All have cost, process and recovery, and morbidity implications which add to treatment decision-making complexity for patients and healthcare professionals. Evidence from randomised controlled trials (RCTs) is not optimal because of uncertainty as to what constitutes important outcomes. Another issue hampering evidence synthesis is heterogeneity of outcome definition, measurement, and reporting. This project aims to determine which outcomes are the most important to patients and healthcare professionals, and use these findings to recommend a standardised core outcome set for comparative effectiveness trials of treatments for localised prostate cancer, to optimise decision-making.

Methods/Design

The range of potentially important outcomes and measures will be identified through systematic reviews of the literature and semi-structured interviews with patients. A consultation exercise involving representatives from two key stakeholder groups (patients and healthcare professionals) will ratify the list of outcomes to be entered into a three round Delphi study. The Delphi process will refine and prioritise the list of identified outcomes. A methodological substudy (nested RCT design) will also be undertaken. Participants will be randomised after round one of the Delphi study to one of three feedback groups, based on different feedback strategies, in order to explore the potential impact of feedback strategies on participant responses. This may assist the design of a future core outcome set and Delphi studies. Following the Delphi study, a final consensus meeting attended by representatives from both stakeholder groups will determine the final recommended core outcome set.

Discussion

This study will inform clinical practice and future trials of interventions of localised prostate cancer by standardising a core outcome set which should be considered in comparative effectiveness studies for localised prostate cancer.
Appendix
Available only for authorised users
Literature
1.
2.
United States Cancer Statistics (USCS): 1999–2010 cancer incidence and mortality data. Centers for Disease Control and Prevention, Division of Cancer Prevention and Control. 2011. http://​apps.​nccd.​cdc.​gov/​uscs/​. Accessed 16 Feb 2015.
3.
Ben-Shlomo Y, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F, et al. The risk of prostate cancer amongst black men in the United Kingdom: The PROCESS cohort study. Eur Urol. 2008;53:99–105.CrossRefPubMed
4.
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–92.CrossRefPubMed
5.
6.
Brewster D, Fraser L, Harris V, Black R. Rising incidence of prostate cancer in Scotland: increased risk or increased detection? BJU Int. 2000;85:463–72. discussion 472–3.CrossRefPubMed
7.
Melia J, Moss S, Johns L. . Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int. 2004;94:51–6.CrossRefPubMed
8.
9.
10.
11.
Shaida N, Malone PR. Open versus laparoscopic radical prostatectomy. The case for open radical prostatectomy. Ann R Coll Surg Engl. 2007;89:108–10.CrossRefPubMed
12.
13.
Eden C. The case for laparoscopic surgery. Ann R Coll Surg Engl. 2007;89:110–2.PubMed
14.
Goldstraw MA, Patil K, Anderson C, Dasgupta P, Kirby RS. A selected review and personal experience with robotic prostatectomy: implications for adoption of this new technology in the United Kingdom. Prostate Cancer Prostatic Dis. 2007;10:242–9.CrossRefPubMed
15.
16.
Donovan JL, Peters TJ, Noble S, Powell P, Gillatt D, Oliver SE, et al. Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). J Clin Epidemiol. 2003;56:605–9.CrossRefPubMed
17.
Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203–13.CrossRefPubMedPubMedCentral
18.
Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol. 2009;55:1037–63.CrossRefPubMed
19.
Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ. 2010;340:c365.CrossRefPubMed
20.
Ramsay C, Pickard R, Robertson C, Close A, Vale L, Armstrong N, et al. Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Health Technol Assess. 2012;16:41.CrossRef
21.
Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148:435–48.CrossRefPubMed
22.
Ip S, Dvorak T, Yu WW, Patel K, Obadan N, Chung M, et al. Comparative Evaluation of Radiation Treatments for Clinically Localized Prostate Cancer: an Update. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Aug. Report No.: CANT1209.
23.
24.
Mowatt G, Scotland G, Boachie C, Cruickshank M, Ford JA, Fraser C, et al. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation. Health Technol Assess. 2013;17:20.CrossRef
25.
Lotan Y, Cadeddu JA, Gettman MT. The new economics of radical prostatectomy: cost comparison of open, laparoscopic and robot assisted techniques. J Urol. 2004;172:1431–5.CrossRefPubMed
26.
Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L, et al. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer. 2006;106:1865–74.CrossRefPubMed
27.
Yossepowitch O, Bjartell A, Eastham JA, Graefen M, Guillonneau BD, Karakiewicz PI, et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol. 2009;55:87–99.CrossRefPubMed
28.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–7.CrossRefPubMed
29.
Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13:132.CrossRefPubMedPubMedCentral
30.
31.
32.
Gargon E, Gurung B, Medley N, Altman DG, Blazeby JM, Clarke M, et al. Choosing important health outcomes for comparative effectiveness research: a systematic review. PLoS One. 2014;9:e99111.CrossRefPubMedPubMedCentral
33.
Chen RC, Chang P, Vetter RJ, Lukka H, Stokes WA, Sanda MG, et al. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst. 2014;106:7.CrossRef
34.
Schellhammer P, Cockett A, Boccon-Gibod L, Gospodarowicz M, Krongrad A, Thompson IM, et al. Assessment of endpoints for clinical trials for localized prostate cancer. Urology. 1997;49(Suppl 4A):27–38.CrossRefPubMed
35.
Denis L, Norlen BJ, Holmberg L, Begg CB, Damber JE, Wilt TJ. Planning controlled clinical trials. Prostatic cancer. Urology. 1997;49(Suppl 4A):15–26.CrossRefPubMed
36.
Feldman-Stewart D, Brundage MD, Tong C. Information that affects patients’ treatment choices for early stage prostate cancer: a review. Can J Urol. 2011;18:5998–6006.PubMed
37.
Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP, et al. Prostate Cancer Clinical Guidelines Panel summary report on the management of clinically localized prostate cancer. J Urol. 1995;154:2144–8.CrossRefPubMed
38.
39.
Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A, et al. Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol. 2014. doi: 10.1016/j.eururo.2014.08.075.
40.
Maclennan SJ, Maclennan SJ, Imamura M, Omar MI, Vale L, Lam T, et al. Urological cancer care pathways: development and use in the context of systematic reviews and clinical practice guidelines. World J Urol. 2011;29:291–301.CrossRefPubMedPubMedCentral
41.
42.
Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors. UICC International Union Against Cancer. 7th ed. Oxford: Wiley-Blackwell; 2009.
43.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41.CrossRefPubMed
44.
45.
Sinha IP, Gallagher R, Williamson PR, Smyth RL. Development of a core outcome set for clinical trials in childhood asthma: a survey of clinicians, parents, and young people. Trials. 2012;13:103.CrossRefPubMedPubMedCentral
46.
Wallace CA, Ruperto N, Giannini E. Childhood Arthritis and Rheumatology Research Alliance, Pediatric Rheumatology International Trials Organization, Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290–4.PubMed
47.
Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP, et al. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25:1229–45.CrossRefPubMed
48.
Ritchie J, Lewis J. Qualitative research practice: a guide for social science students and researchers. London: Sage; 2003.
49.
Harman NL, Bruce IA, Callery P, Tierney S, Sharif MO, O’Brien K, et al. MOMENT: Management of Otitis Media with Effusion in Cleft Palate: protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials. 2013;14:70.CrossRefPubMedPubMedCentral
50.
Taylor WJ, Schumacher HR, Baraf HSB, Chapman P, Stamp L, Doherty M, et al. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis. 2008;67:888–91.CrossRefPubMed
51.
Macefield R, Blencowe N, Brookes S, Jacobs M, Sprangers M, Williamson PR, et al. Core outcome set development: the effect of Delphi panel composition and feedback on prioritisation of outcomes. Trials. 2014;14 Suppl 1:77.CrossRef
52.
Metadata
Title
A core outcome set for localised prostate cancer effectiveness trials: protocol for a systematic review of the literature and stakeholder involvement through interviews and a Delphi survey
Authors
Steven MacLennan
Hendrika J Bekema
Paula R Williamson
Marion K Campbell
Fiona Stewart
Sara J MacLennan
James MO N’Dow
Thomas BL Lam
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Trials / Issue 1/2015
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-015-0598-0

Other articles of this Issue 1/2015

Trials 1/2015 Go to the issue

Study protocol

Preventing anxiety problems in children with Cool Little Kids Online: study protocol for a randomised controlled trial

Study protocol

BASIC study: is intravaginal boric acid non-inferior to metronidazole in symptomatic bacterial vaginosis? Study protocol for a randomized controlled trial

Study protocol

Titanium versus absorbable tacks comparative study (TACS): a multicenter, non-inferiority prospective evaluation during laparoscopic repair of ventral and incisional hernia: study protocol for randomized controlled trial

Study protocol

Comparison of two surgical methods for the treatment of CIN: classical LLETZ (large-loop excision of the transformation zone) versus isolated resection of the colposcopic apparent lesion – study protocol for a randomized controlled trial

Study protocol

Efficacy of acupuncture and electroacupuncture in patients with nonspecific low back pain: study protocol for a randomized controlled trial

Study protocol

Center for stroke disparities solutions community- based care transition interventions: study protocol of a randomized controlled trial